Gareth P. Gregory, MBBS, PhD

Department of Hematology, School of Clinical Sciences at Monash Health, Monash University, Australia

N/A

Poster(s):

• 2005 - A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies